Effects of Liraglutide in Chronic Obstructive Pulmonary Disease

NCT03466021 on ClinicalTrials.gov · last registry update 2021-03-16

Finished 31 May 2020, after enrolling 40 people. Primary outcome, as filed: Transition Dyspnea Index (TDI).

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Claus Bogh Juhl
Sponsor type: Other
Enrollment: 40
Started: 2018-01-01
Primary completion: 2020-05-31 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Transition Dyspnea Index (TDI)

Conditions studied

Pulmonary Disease, Chronic Obstructive

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.